Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

March 24, 2020March 24, 2020

Epidiolex Still Effective at Half the Highest Approved Dose for Reducing Frequency of Convulsive Seizures in Children with Dravet

News

Epidiolex (cannabidiol), as an add on-therapy administered at either a low or high dose, leads to similar clinically relevant reductions in the frequency of convulsive seizures in children with treatment-resistant Dravet ... Read more

March 9, 2020March 9, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

February 28, 2020February 28, 2020

FDA Extends Review of Fintepla for Dravet Syndrome; Response Expected in June

News

The U.S. Food and Drug Administration (FDA) extended by three months the review period for Zogenix’s New Drug Application (NDA) for Fintepla (ZX008), an investigational anti-seizure therapy for patients with Dravet syndrome. ... Read more

November 26, 2019December 18, 2019

Fintepla Lowers Seizure Frequency in Children and Teens with Dravet, Phase 3 Studies Report

News

Editor’s note: This story has been updated to add that Zogenix resubmitted a new drug application for Fintepla to the FDA in late September. Treatment with Fintepla (ZX008) can ... Read more

October 29, 2019October 29, 2019

NeuCyte, Trillium Therapeutics Team Up to Develop New Therapy for Drug-resistant Epilepsies

News

Neucyte and Trillium Therapeutics have established a license agreement to develop a new therapy for drug-resistant epilepsies, including Dravet syndrome and related disorders. The agent, whose name is still undisclosed, ... Read more

August 27, 2019August 27, 2019

Stoke Therapeutics’ STK-001 Granted Orphan Drug Designation by FDA

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation — allowing various development incentives — to Stoke Therapeutics’ STK-001 for the treatment of Dravet syndrome. The ... Read more

August 20, 2019October 8, 2019

EU Approval of Oral Cannabidiol as Add-On Therapy for Dravet Favored by CHMP

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), is recommending approval of GW Pharmaceutical’s oral cannabidiol solution as an add-on to clobazam (Onfi and Sympazan) for treating seizures ... Read more

July 23, 2019July 23, 2019

Encoded Earns $104M in Financing to Advance Potential Gene Therapy for Dravet

News

Encoded Therapeutics will further develop its lead precision gene therapy platform for Dravet syndrome and other severe genetic disorders after a financing round brought in $104 million from several ... Read more

July 9, 2019July 9, 2019

Zogenix Resubmitting New Drug Application to FDA for Fintepla Anti-Seizure Therapy

News

Zogenix has announced it will resubmit a New Drug Application (NDA) for Fintepla (ZX008), its investigational anti-seizure therapy for patients with Dravet syndrome, likely in the third quarter of this ... Read more

July 2, 2019October 8, 2019

Epygenix Submits Investigational New Drug Application for Dravet Therapy

News

Epygenix Therapeutics has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to assess the safety and efficacy of EPX-100, its investigational ... Read more

Pin It on Pinterest